EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Characteristics and Management of Rituximab-Induced Infusion-Related Reactions in Thai Patients with Hematologic Malignancies: A Retrospective Observational Study

Kamala Sadabpod, Chakkrit Jaidee, Benjarat Engmahatsakun, Kulthida Neamnil, Saranporn Srithonrat, Chayanat Pongsathabordee, Taniya Paiboonvong

Hematology Reports · 13.11.2026 · 18 (6) · 85

DOI: 10.3390/hematolrep18060085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 13.11.2026. Verfasst von Kamala Sadabpod und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Rituximab has been widely used for the treatment of cancers, and the occurrence of infusion-related reactions (IRRs) is one of the main concerns. Although rituximab-associated IRRs have been well documented, data specifically describing IRRs among Thai patients with hematologic malignancies remain limited. This study aimed to determine the clinical characteristics and management of IRRs to rituximab among Thai patients with hematologic malignancies.

Methods

This retrospective descriptive study included 100 patients with hematologic malignancies who received rituximab at a super-tertiary care hospital in Thailand between January 2019 and September 2020. Data were analyzed using descriptive statistics. Categorical variables were presented as frequencies and percentages, while continuous variables were summarized as median with interquartile ranges.

Results

IRRs occurred in 9 patients (9.0%) following rituximab administration. Most patients were aged≥ 60 years (52%). Females were predominant (58.0%). Non-Hodgkin lymphoma (NHL) was commonly diagnosed in 75% of patients. The biosimilar rituximab, Truximab®, was the most commonly prescribed formulation (54.0%). All reactions were classified as grade 2 and occurred during the first infusion (88.9%). Chills were the most common symptom. The median time to IRR onset was 60 min. IRRs were commonly managed by temporarily interrupting the infusion and reducing the infusion rate before resuming administration. Antihistamines were frequently administered to relieve symptoms. No severe reactions were observed after management of reactions.

Conclusions

The proportion of patients experiencing IRRs was relatively low, with all reactions classified as mild to moderate severity. Most reactions occurred during the first infusion, typically within the first hour of administration. These findings highlight the importance of close monitoring during the first infusion and timely management to ensure patient safety. Standardized management protocols may further support consistent clinical practice.

Zitieren

APA

Sadabpod, K., Jaidee, C., Engmahatsakun, B., Neamnil, K., Srithonrat, S., Pongsathabordee, C., & Paiboonvong, T. (2026). Clinical Characteristics and Management of Rituximab-Induced Infusion-Related Reactions in Thai Patients with Hematologic Malignancies: A Retrospective Observational Study. Hematology Reports, 18(6), 85. https://doi.org/10.3390/hematolrep18060085

Vancouver

Sadabpod K, Jaidee C, Engmahatsakun B, Neamnil K, Srithonrat S, Pongsathabordee C, et al. Clinical Characteristics and Management of Rituximab-Induced Infusion-Related Reactions in Thai Patients with Hematologic Malignancies: A Retrospective Observational Study. Hematology Reports. 2026;18(6):85. doi:10.3390/hematolrep18060085

BibTeX
@article{Sadabpod2026,
  author = {Sadabpod, Kamala and Jaidee, Chakkrit and Engmahatsakun, Benjarat and Neamnil, Kulthida and Srithonrat, Saranporn and Pongsathabordee, Chayanat and Paiboonvong, Taniya},
  title = {Clinical Characteristics and Management of Rituximab-Induced Infusion-Related Reactions in Thai Patients with Hematologic Malignancies: A Retrospective Observational Study},
  journal = {Hematology Reports},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {85},
  doi = {10.3390/hematolrep18060085}
}
Kostenlos starten →